Back to News
Market Impact: 0.35

Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

Company FundamentalsCorporate Guidance & OutlookM&A & RestructuringHealthcare & Biotech
Collegium Pharmaceutical Stock Gains 12% in Three Months: Here's Why

COLL momentum improved as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and overall revenue outlook. The update supports confidence in the company’s growth trajectory for 2026 and helps reinforce expectations for continued franchise expansion.

Analysis

COLL momentum improved as strong Jornay PM growth and the Azstarys acquisition boosted 2026 guidance, strengthening its ADHD franchise and overall revenue outlook. The update supports confidence in the company’s growth trajectory for 2026 and helps reinforce expectations for continued franchise expansion.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Demo

Market Sentiment

Overall Sentiment

mildly positive

Sentiment Score

0.35

Ticker Sentiment

More News